Andreas Linkermann

Andreas Linkermann

@linkermannlab.bsky.social

Chair 5th Med Dept UMM, Heidelberg University Kidney Transplantation and Cell Death Biology

137 followers150 following14 posts

Andreas Linkermann reposted

Thrilled to have contributed to this work led by @jgcastillo.bsky.social during his PhD at UC Berkeley w/ Michel DuPage. Targeting FSP1 in T cells boosts anti-tumor immunity by relieving Treg suppression, revealing a new immunomodulatory therapeutic axis. www.science.org/doi/10.1126/...

science.orgSelective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunityDeletion of Aifm2 disrupts Treg cell immunosuppression within tumors without inciting autoimmune pathology in mice.

Reviewing the paper by the Kats´ lab published today in #Cell, "Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia", I learned that cuproptosis is real! Here is my preview: When heme is low, copper kills cancer: www.cell.com/cell/fulltex...

cell.comWhen heme is low, copper kills cancerHeme carries oxygen and is critical for the control of redox reactions. In this issue of Cell, Lewis and Gruber et al. demonstrate how low concentrations of heme destabilize complex IV of the respirat...

Andreas Linkermann reposted

Hot off the presses! Was an honor to team up with Scott Dixon @stanforduniversity.bsky.social on this Nature Cancer review. We reflect on hurdles that have slowed translation of ferroptosis-directed therapies and share ideas on what it will take to bring these therapies to the clinic. rdcu.be/eBbqV

rdcu.beProspects for ferroptosis therapies in cancerNature Cancer - Ubellacker and Dixon summarize the latest discoveries on ferroptosis in cancer, covering the molecular and cellular pathways underlying sensitivity and resistance to this type of...
Harvard Molecular Metabolism@met-hsph.bsky.social

Ferroptosis-targeting therapies in cancer have yet to make it to the clinic. New review published today in Nature Cancer by @ubellackerlab.bsky.social and Scott Dixon of Stanford share hurdles and ideas for future strategies to bring these therapies closer to the clinic. Check it out rdcu.be/eBbqV

You are up to date.